Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and olderAndres Forero‐Torres, Christopher A. Yasenchak, Gregg A. Olsen et al.|Blood|2015Cited by 142
Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.Jonathan W. Friedberg, Christopher A. Yasenchak, Andres Forero‐Torres et al.|Journal of Clinical Oncology|2018Cited by 4